
Elbit Systems wins $200 million Asia-Pacific contracts
- Elbit Systems secured approximately $200 million in contracts from an undisclosed Asia-Pacific country to supply airborne intelligence, surveillance, targeting and training systems.
- The contracts cover SPECTRO 12 multispectral surveillance payloads for helicopters, upgrades to airborne training systems and advanced Head-Up Displays.
- Elbit expects to execute the contracts over up to five years, expanding its airborne defense technology business in the Asia-Pacific region.
Elbit Systems (NASDAQ:ESLT) announced approximately $200 million in contracts to supply airborne intelligence, surveillance, targeting and training solutions to an undisclosed Asia-Pacific country.
The contracts will be performed over up to five years and include helicopter surveillance equipment, aircraft training system upgrades and advanced cockpit displays.
“Elbit Systems' airborne solutions combine advanced technologies with extensive operational experience across a wide range of mission environments,” said Elbit Systems President and CEO Bezhalel Machlis.
Elbit will supply its SPECTRO 12 multispectral surveillance and targeting payload, designed to combine high-resolution imaging, laser designation and AI-powered processing for helicopter operations.
The agreements also cover follow-on support for existing airborne training systems, including simulated air-to-air and air-to-ground missions, weapon scoring and mission debriefing capabilities.
Elbit will deliver Head-Up Display systems featuring high-resolution imaging, enhanced video capabilities and low power consumption for day and night operations.
The announcement follows a separate $270 million agreement in September 2026 to supply advanced surveillance and targeting payloads to another international customer.
Frequently asked questions
More from United States
Oil prices fall 2% on Iran diplomacy hopes
HUTCHMED reports 32% lower death risk in lung cancer trial
Bristol Myers lung cancer trial shows 11.1-month PFS
Bristol Myers shares fall 2.4% after fatal trial event
Tango Reports 82% Response Rate in Pancreatic Cancer Trial
Zai Lab reports 81.8% response rate in lung cancer trial



